Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection

por Solms, Alexander, Lalezari, Shadan, Shah, Anita, Kenet, Gili
Publicado 2020

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophi...

por Shah, Anita, Solms, Alexander, Garmann, Dirk, Katterle, Yvonne, Avramova, Verzhiniya, Simeonov, Stanislav, Lissitchkov, Toshko
Publicado 2016

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches

por Ruehs, Hauke, Solms, Alexander, Frei, Matthias, Becker, Corina, Trujillo, Maria E., Garmann, Dirk, Meyer, Michaela
Publicado 2023

Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII

por Abrantes, João A., Solms, Alexander, Garmann, Dirk, Nielsen, Elisabet I., Jönsson, Siv, Karlsson, Mats O.
Publicado 2019

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

por Abrantes, João A., Solms, Alexander, Garmann, Dirk, Nielsen, Elisabet I., Jönsson, Siv, Karlsson, Mats O.
Publicado 2020

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach

por Solms, Alexander, Iorio, Alfonso, Ahsman, Maurice J., Vis, Peter, Shah, Anita, Berntorp, Erik, Garmann, Dirk
Publicado 2019

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin

por Busse, David, Schaeftlein, André, Solms, Alexander, Ilia, Luis, Michelet, Robin, Zeitlinger, Markus, Huisinga, Wilhelm, Kloft, Charlotte
Publicado 2021

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

por Willmann, Stefan, Zhang, Liping, Frede, Matthias, Kubitza, Dagmar, Mueck, Wolfgang, Schmidt, Stephan, Solms, Alexander, Yan, Xiaoyu, Garmann, Dirk
Publicado 2018

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

por Shah, Anita, Solms, Alexander, Wiegmann, Sara, Ahsman, Maurice, Berntorp, Erik, Tiede, Andreas, Iorio, Alfonso, Mancuso, Maria Elisa, Zhivkov, Tihomir, Lissitchkov, Toshko
Publicado 2019

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

por Solms, Alexander, Shah, Anita, Berntorp, Erik, Tiede, Andreas, Iorio, Alfonso, Linardi, Camila, Ahsman, Maurice, Mancuso, Maria Elisa, Zhivkov, Tihomir, Lissitchkov, Toshko
Publicado 2020

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free m...

por Chen, Rong, Gultyaev, Dmitry, Lister, Johanna, Han, Rong, Hu, Nan, Malacan, Jean, Solms, Alexander, Vashi, Parth, O’Hara, Jamie, Hu, Shanlian
Publicado 2022

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study

por Santoro, Cristina, Fuh, Beng, Le, Phu Quoc, Maes, Philip, Berrueco, Rubén, Mingot‐Castellano, Eva Maria, von Mackensen, Sylvia, Solms, Alexander, Wang, Michael
Publicado 2020

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

por Solms, Alexander, Frede, Matthias, Berkowitz, Scott D., Hermanowski‐Vosatka, Anne, Kubitza, Dagmar, Mueck, Wolfgang, Spiro, Theodore E., Willmann, Stefan, Yan, Xiaoyu, Zhang, Liping, Garmann, Dirk
Publicado 2019

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism

por Reinecke, Isabel, Solms, Alexander, Willmann, Stefan, Spiro, Theodore E., Peters, Gary, Weitz, Jeffrey I., Mueck, Wolfgang, Garmann, Dirk, Schmidt, Stephan, Zhang, Liping, Fox, Keith A. A., Berkowitz, Scott D.
Publicado 2020

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation

por Zhang, Liping, Yan, Xiaoyu, Fox, Keith A. A., Willmann, Stefan, Nandy, Partha, Berkowitz, Scott D., Hermanowski-Vosatka, Anne, Weitz, Jeffrey I., Solms, Alexander, Schmidt, Stephan, Patel, Manesh, Peters, Gary
Publicado 2020

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism

por Solms, Alexander, Willmann, Stefan, Reinecke, Isabel, Spiro, Theodore E., Peters, Gary, Weitz, Jeffrey I., Mueck, Wolfgang, Garmann, Dirk, Schmidt, Stephan, Zhang, Liping, Fox, Keith A. A., Berkowitz, Scott D.
Publicado 2020

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis

por Hilpert, Jan, Groettrup-Wolfers, Esther, Kosturski, Hristiyan, Bennett, Laura, Barnes, Catriona L. K., Gude, Kerstin, Gashaw, Isabella, Reif, Stefanie, Steger-Hartmann, Thomas, Scheerans, Christian, Solms, Alexander, Rottmann, Antje, Mao, Guangping, Chapron, Charles
Publicado 2023

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

por Willmann, Stefan, Marostica, Eleonora, Snelder, Nelleke, Solms, Alexander, Jensen, Markus, Lobmeyer, Maximilian, Lensing, Anthonie W. A., Bethune, Claudette, Morgan, Erin, Yu, Rosie Z., Wang, Yanfeng, Jung, Shiangtung W., Geary, Richard, Bhanot, Sanjay
Publicado 2021